Floatz logo

Tucatinib

LMD

Sunnybrook Health Sciences CentreSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the LMD cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Sunnybrook Health Sciences Centre
Phase 2CCC
Eloxatin
Sunnybrook Health Sciences Centre
Phase 2CCC
qbs72s
Stanford University
Phase 2CCC
Capecitabine
Sunnybrook Health Sciences Centre
Phase 2CCC

Same molecule, other indications

Tucatinib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
invasive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →